oclacitinib

05/04/2023 - "This study aimed to evaluate the immediate/delayed pruritus responses and the pruritic behaviors observed in an intradermal IL-31-induced pruritic model of healthy dogs and the anti-pruritic effect of oclacitinib on said model. "
04/01/2023 - "Die anfängliche Zugabe von Prednisolon für vier Tage reduzierte die Wahrscheinlichkeit eines Pruritus Rebounds eine Woche nach Dosisreduzierung des Oclacitinib signifikant. "
04/01/2021 - "Die topische Verabreichung von 0,0584%igem HCA Spray könnte sich bei Hunden mit cAD gut auf eine Verschlimmerung des Pruritus und der klinischen Läsionen auswirken, wenn die Behandlungsdosis mit Oclacitinib langsam reduziert wird. "
04/01/2019 - "Oclacitinib scheint zur Behandlung des Pruritus und der Hautveränderungen bei Katzen mit NFNFIHD wirksam zu sein, wobei allerdings Methylprednisolon eine etwas bessere Wirkung zeigte. "
02/01/2019 - "Although a limited number of dogs were investigated, these preliminary results suggest that oclacitinib appears to have immunosuppressive properties, but only at dosages above those used to treat allergic pruritus in dogs."

01/01/2022 - "Additionally, topical oclacitinib was shown to improve an induced model of dermatitis in mice. "
04/01/2023 - "HIPÓTESIS/OBJETIVOS: Evaluamos el número de células Treg y los niveles séricos de interleuquina (IL)-10 y factor de crecimiento transformante-beta (TGF-β)1 en perros diagnosticados con dermatitis atópica (AD) y tratados con éxito con ciclosporina u oclacitinib durante nueve o mas meses ANIMALES: Incluimos 15 perros que recibieron oclacitinib, 14 perros tratados con ciclosporina, 15 perros sanos, 13 perros con AD de moderada a grave no tratada y 15 perros atópicos controlados con AIT. "
04/01/2023 - "INTRODUCCIÓN: ocasionalmente se produce una recidiva del prurito después de la reducción de la dosis de oclacitinib en perros con dermatitis atópica (AD). "
01/01/2023 - "Veterinarian assessment showed a 70% reduction in dermatitis severity over time (p < 0.05), supporting oclacitinib's anti-inflammatory effects. "
01/01/2023 - "Diminished antimicrobial drug use in dogs with allergic dermatitis treated with oclacitinib."

03/17/2022 - "Dogs that were enrolled in the study were client-owned, ranged from 1 to 14 years of age, weighed 3.7 to 60.7 kg, and required twice daily treatment with Apoquel for allergic or atopic dermatitis for 7 days. "
08/01/2019 - "Enrolled dogs had exhibited control of atopic dermatitis on oclacitinib for at least 6 months before, and continuing throughout, the study. "
04/01/2022 - "The medical records of dogs with atopic dermatitis treated with oclacitinib twice daily for more than two weeks were reviewed retrospectively. "
04/01/2022 - "Prolonged twice-daily administration of oclacitinib for the control of canine atopic dermatitis: a retrospective study of 53 client-owned atopic dogs."
08/01/2021 - "Oclacitinib, used at the standard dose range recommended for the treatment of canine atopic dermatitis, effectively resolved ETUD in 22 of 25 dogs within one to three months. "

10/01/2017 - "The use of oclacitinib may be useful for the treatment of some autoimmune skin diseases in dogs. "
04/27/2022 - "This study demonstrates a potential sparing effect of oclacitinib on the prescription of antimicrobials for the treatment of allergic skin diseases in dogs. "
10/01/2017 - "A case of presumed autoimmune subepidermal blistering dermatosis treated with oclacitinib."
06/01/2015 - "Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life."
06/01/2015 - "Two hundred and forty-seven client-owned dogs with allergic skin disease that had previously benefited from oclacitinib therapy. "

12/01/2019 - "Kravetz de Oliveira J, Williams DL, Bollmann C et al. Comparative efficacy of topical oclacitinib 0.1 % and tacrolimus 0.01 % in canine keratoconjunctivitis sicca. "
09/01/2019 - "To assess the efficacy of 0.1% oclacitinib as a single agent, and in combination with tacrolimus 0.01%, for the control of ophthalmic signs of keratoconjunctivitis sicca (KCS) in dogs. "
09/01/2019 - "Comparative efficacy of topical oclacitinib 0.1% and tacrolimus 0.01% in canine keratoconjunctivitis sicca."